3 completed, 2 terminated. 3 Phase 4, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Hurler's Syndrome: new trials by email Literature Review of Hurler's Syndrome trials Research Report on Hurler's Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants Laronidase - Mucopolysaccharidosis I, Hurler's Syndrome | Phase 4 | Terminated | Genzyme, a Sanofi Company | 2 | 2010-10-22 | 2024-02-20 |
| Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Stem Cell Transplantation, Cyclophosphamide, Campath-1H - Hurler's Syndrome, Maroteaux-Lamy Syndrome | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 18 | 2008-03-01 | 2017-12-28 |
| A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease Aldurazyme (Recombinant Human Alpha-L-Iduronidase) - Mucopolysaccharidosis I, Hurler's Syndrome | Phase 4 | Completed | Genzyme, a Sanofi Company | 34 | 2004-12-01 | 2015-04-03 |
| A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients laronidase - Mucopolysaccharidosis I, Hurler's Syndrome | Phase 4 | Completed | Genzyme, a Sanofi Company | 25 | 2004-07-01 | 2014-05-05 |
| Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients Aldurazyme, placebo - Mucopolysaccharidosis I, Hurler's Syndrome | Phase 3 | Completed | Genzyme, a Sanofi Company | 45 | 2001-05-01 | 2015-04-03 |
Mucopolysaccharidosis I (5) · Aspartylglucosaminuria (1) · Fucosidosis (1) · Leukodystrophy, Globoid Cell (1) · Leukodystrophy, Metachromatic (1) · Metabolism, Inborn Errors (1) · Mucopolysaccharidosis VI (1) · Mucopolysaccharidosis VII (1) · Niemann-Pick Disease, Type B (1) · Niemann-Pick Disease, Type C (1) · Peroxisomal Disorders (1) · Sphingolipidoses (1) · Wolman Disease (1) · alpha-Mannosidosis (1)
Carbohydrate Metabolism, Inborn Errors (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Connective Tissue Diseases (5) · Genetic Diseases, Inborn (5) · Lysosomal Storage Diseases (5) · Metabolic Diseases (5) · Mucinoses (5) · Mucopolysaccharidoses (5) · Nutritional and Metabolic Diseases (5) · Skin and Connective Tissue Diseases (5) · Metabolism, Inborn Errors (4) · Brain Diseases (1) · Brain Diseases, Metabolic (1) · Brain Diseases, Metabolic, Inborn (1) · Central Nervous System Diseases (1)
Iduronidase (4) · Alemtuzumab (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Cyclophosphamide (1) · Stem Cell Transplantation (1)
Genzyme, a Sanofi Company (4) · Masonic Cancer Center, University of Minnesota (1)
United States (3) · Brazil (2) · Canada (2) · Italy (2) · Germany (1) · Netherlands (1) · United Kingdom (1)
Paul Orchard, MD (1)